FIELD: chemistry.
SUBSTANCE: present invention relates to immunology. Proposed is a binding agent that is a bispecific antibody containing a claudin binding domain (CLDN), namely CLDN18.2, and a CD3 binding domain. Also a nucleic acid, a vector and a host cell are proposed for expressing said agent. In addition, a pharmaceutical composition and a method for treating or preventing cancer are described, which is characterized by cancer cells expressing CLDN18.2.
EFFECT: agent of the present invention is able to induce strong T-cell mediated lysis and is effective in the treatment of neoplastic diseases.
22 cl, 40 dwg, 12 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENTS FOR THE TREATMENT OF CLAUDINE-EXPRESSING CANCER DISEASES | 2013 |
|
RU2798990C2 |
| BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN 6 OR CLAUDIN 18.2 AND CD3 FOR THE TREATMENT OF ONCOLOGICAL DISEASES WITH CLAUDIN EXPRESSION | 2017 |
|
RU2798988C2 |
| COMBINED THERAPY WITH USE OF CLAUDIN 18,2 ANTIBODIES FOR CANCER TREATMENT | 2013 |
|
RU2662066C2 |
| COMBINED THERAPY USING THE ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2665321C2 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| DIAGNOSTICS AND TREATMENT OF CANCER ASSOCIATED WITH CANCER STEM CELLS | 2014 |
|
RU2749867C2 |
| ANTIBODIES SPECIFIC TO CLAUDIN 6 (CLDN6) | 2010 |
|
RU2675997C2 |
| COMBINATION THERAPY USING ANTIBODIES TO CLAUDIN 18.2 FOR TREATMENT OF CANCER | 2013 |
|
RU2789478C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| ANTIBODIES BOUND TO EXTRACELLULAR DOMAIN OF TYROSINE KINASE RECEPTOR (ALK) | 2007 |
|
RU2460540C2 |
